srx acquisition target

Although the organic growth scenario works well,I am quite confident that SRX is being eyed pretty good by a big company ,as the growth here is terrific with a very low valuation. There are very few niche oncology copmpanies like SRX with such good growth and potential. If Cephalon bid $5, five years ago when company had 25 centers and o profits, now that it has over 200 worldwide centers and is very profitable, then now the value to an acquirer is many times higher.Any deal will go through Dr Gray and Hunter Hall and I believe now they would accept double figures.